Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Company Overview

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH).

Stock Snapshot

IR Contacts

Headquarters

Inhibikase Therapeutics, Inc.
1000 N. West Street
Suite 1200
Wilmington, DE 19801
info@inhibikase.com

Investor Relations

LifeSci Advisors
Mike Moyer
Managing Director
T: 617-308-4306
mmoyer@lifesciadvisors.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
T: 800-937-5449
help@astfinancial.com
https://www.astfinancial.com